Wegovy for NASH: Off-Label Use, Evidence, and Monitoring

Semaglutide is a GLP-1 receptor agonist. Wegovy is the brand name for the 2.4 mg once-weekly subcutaneous formulation, FDA-approved for chronic weight management. Ozempic is the same molecule at lower weekly doses (up to 2.0 mg), FDA-approved for type 2 diabetes. Neither product carries an FDA indication for NASH, MASH, or any liver disease. Using either drug for liver disease is off-label prescribing, meaning a licensed provider is choosing to use an approved drug outside its labeled indication based on their clinical judgment and the available evidence, not based on an FDA-reviewed liver indication.

The useful question for a patient or caregiver is not "is Wegovy approved for NASH" (it is not) but "how strong is the off-label evidence, and what should monitoring look like if a provider decides to use it anyway." That is what this page addresses.

The direct answer, with its boundary

Wegovy has no FDA-approved indication for NASH or MASH as of May 2026. The off-label rationale rests mainly on a phase 2 randomized, placebo-controlled trial of a related daily semaglutide dose that reported improved liver inflammation (NASH resolution) at 72 weeks, without a statistically significant improvement in fibrosis, plus supportive metabolic and cardiovascular data from the weight-loss trial program for the 2.4 mg weekly formulation. Fibrosis, the change that predicts long-term liver outcomes, has not yet been shown to improve significantly with semaglutide in a completed, fully published trial. That gap is the central limitation a prescriber and patient need to weigh before starting therapy for liver disease specifically.

What NASH and MASH mean, and why the name changed

NASH (nonalcoholic steatohepatitis) describes a form of fatty liver disease with hepatocyte inflammation, ballooning injury, and variable fibrosis. In 2023, a multi-society consensus process renamed the disease MASH (metabolic dysfunction-associated steatohepatitis) to emphasize its metabolic drivers and move away from the "nonalcoholic" framing. The two terms describe the same underlying disease process; MASH is the current preferred term. (The exact consensus statement should be confirmed against the current AASLD/EASL nomenclature publication before this history is cited elsewhere on the site.)

Fatty liver disease broadly (MASLD) is common in people with obesity, insulin resistance, or type 2 diabetes, and a meaningful subset of those patients progress to the more inflamed, fibrosis-prone MASH stage. Untreated, MASH can progress toward cirrhosis and, in a minority of patients, hepatocellular carcinoma or the need for liver transplant. GLP-1 receptor agonists draw interest here because they lower body weight, improve insulin sensitivity, and reduce markers of systemic inflammation, three pathways that overlap with what drives MASH.

Wegovy's approved indication versus the off-label NASH rationale

The FDA approved Wegovy (semaglutide 2.4 mg subcutaneous, once weekly) in 2021 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with comorbid conditions including hypertension, type 2 diabetes, or dyslipidemia. Neither NASH nor MASH appears in the approved indication.

Resmetirom (Rezdiffra), a thyroid hormone receptor beta agonist, received FDA accelerated approval in March 2024 specifically for adults with MASH and moderate to advanced liver fibrosis (stages F2 to F3), used alongside diet and exercise. Resmetirom acts directly on liver metabolism. Semaglutide acts systemically, through weight loss and improved insulin sensitivity. These are different mechanisms, and some hepatologists have discussed combining the two, though no completed trial has tested that combination.

Because resmetirom has a fibrosis-specific approval and semaglutide does not, a patient whose primary concern is liver fibrosis staging (F2 to F3) has a more direct, FDA-reviewed option to discuss with their hepatologist before considering an off-label GLP-1 approach.

What the phase 2 semaglutide-in-NASH trial actually showed

The main clinical trial evidence for semaglutide in NASH is a phase 2, randomized, double-blind, placebo-controlled study (Newsome et al., published in the New England Journal of Medicine, 2021) in adults with biopsy-confirmed NASH and fibrosis stages F1 through F3. Participants received daily subcutaneous semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg, or placebo, for 72 weeks. The 0.4 mg daily dose is considered pharmacokinetically comparable to the 2.4 mg weekly Wegovy dose, though the two have not been directly compared in a liver-biopsy trial.

The trial reported that a clear majority of patients on the highest semaglutide dose achieved NASH resolution (disappearance of hepatocyte ballooning) without worsening fibrosis, compared with a small minority on placebo, a difference the authors described as statistically significant. Fibrosis improvement (a one-stage or greater reduction) was numerically higher with semaglutide than placebo but did not reach statistical significance, a result the investigators attributed at least partly to the trial not being powered to detect a fibrosis difference. Weight loss and ALT reductions tracked together in the trial.

The exact percentage figures reported in this trial (NASH resolution rate, fibrosis improvement rate, ALT change) should be verified against the original NEJM publication before being published as precise numbers; this draft intentionally avoids restating exact percentages without that direct verification.

Patients with compensated cirrhosis (F4 fibrosis) were excluded from this trial, so its findings do not extend to that population.

Supporting data from the weight-loss and cardiovascular trial program

The STEP program of trials, which established Wegovy's obesity indication, was not designed as a liver trial, but post hoc and mechanistic work in that population has reported reductions in ALT among participants with elevated baseline liver enzymes, consistent with the known effect of substantial weight loss on hepatic fat. A separate large cardiovascular outcomes trial in adults with overweight or obesity and established cardiovascular disease (SELECT) reported a reduction in major adverse cardiovascular events with semaglutide 2.4 mg; it did not include liver biopsy endpoints. That cardiovascular signal is clinically relevant to MASH patients because cardiovascular disease, not liver failure, is the most common cause of death in people with fatty liver disease broadly, though the precise comparative mortality data should be confirmed against a current epidemiology reference before it is cited as a hard number.

Novo Nordisk has reported interim topline results from ESSENCE, a phase 3 trial of semaglutide 2.4 mg weekly specifically in MASH with fibrosis, stating that the trial met its primary endpoint of NASH resolution without fibrosis worsening. As of May 2026, full peer-reviewed results for ESSENCE had not been published. Until the peer-reviewed paper is available, ESSENCE should be treated as manufacturer-reported interim data, not as an independently confirmed trial result, and any fibrosis-specific claim from it should wait for publication.

Who is a reasonable candidate for off-label Wegovy in NASH

Decision framework: should off-label Wegovy for NASH be on the table?

This framework does not replace an individualized recommendation. It is meant to structure the conversation between a patient and their prescriber about where the current evidence is strong, where it is promising but unproven, and where it does not apply.

Monitoring if a provider prescribes Wegovy off-label for NASH

Standard Wegovy label monitoring covers gastrointestinal tolerability, heart rate, and pancreatitis risk. Off-label liver use calls for additional, liver-specific tracking.

Before starting

• Liver enzymes: ALT, AST, GGT, alkaline phosphatase
• Fibrosis assessment: FIB-4 index (calculated from age, ALT, AST, and platelet count), and ideally elastography (FibroScan) or MRI-PDFF where available
• Metabolic panel: HbA1c, fasting glucose, lipid panel, serum creatinine
• Weight, BMI, waist circumference
• Liver biopsy is not routine for everyone; it is more often considered when noninvasive tests are indeterminate, when a clinical trial requires histologic confirmation, or when another liver disease is suspected

During dose escalation

Wegovy follows a fixed titration over roughly 16 to 20 weeks up to the 2.4 mg maintenance dose. During escalation:

• Check ALT and AST at an early point (for example, around week 4) and again around week 12
• Track gastrointestinal side effects, which are most common during escalation
• Watch for symptoms of pancreatitis (persistent, severe abdominal pain radiating to the back) and seek urgent care if these occur
• Record weight at each visit

After reaching the maintenance dose

• Every 3 months in the first year: ALT, AST, weight, HbA1c if diabetic or prediabetic, symptom check
• Every 6 months: FIB-4 recalculation, lipid panel
• Every 6 to 12 months: repeat elastography or MRI-PDFF where feasible, to track steatosis and fibrosis trends
• Annually: broader metabolic and cardiovascular risk reassessment

Warning signs that require prompt evaluation, not routine follow-up

An ALT rise well above the upper limit of normal during treatment should prompt evaluation for causes other than the underlying liver disease, including drug-induced liver injury, viral hepatitis, autoimmune hepatitis, or biliary obstruction. New jaundice, easy bruising or bleeding, confusion, or marked abdominal swelling are signs that need urgent medical attention and should prompt stopping the drug pending evaluation, not a wait-and-see approach.

What is established, what is plausible, and what is not established

Established: Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management, not for liver disease. Resmetirom is the only FDA-approved drug specifically for MASH with fibrosis, as of its 2024 accelerated approval. Off-label prescribing of Wegovy for NASH is legal when a licensed provider judges it appropriate.

Plausible but not yet confirmed: That semaglutide, through weight loss and metabolic improvement, meaningfully improves liver fibrosis over time. Interim data from a dedicated phase 3 MASH trial (ESSENCE) point in this direction, but full peer-reviewed results were not available as of May 2026.

Not established: A statistically confirmed fibrosis benefit from semaglutide in a completed, published trial. Long-term outcomes (progression to cirrhosis, liver-related mortality) with semaglutide use in MASH. The comparative effectiveness of semaglutide versus resmetirom, or of combining the two, since no trial has tested that combination directly.

Practical considerations

Cost and coverage

Wegovy carries a substantial monthly list price in the United States, and coverage for an off-label liver indication is inconsistent among insurers as of 2026. Many NASH patients also meet the approved obesity criteria (BMI ≥30, or ≥27 with a weight-related comorbidity), and documenting obesity as the primary diagnosis is generally what supports insurance approval, since that is the FDA-reviewed indication. Manufacturer savings programs exist and change over time; current terms should be checked directly on Novo Nordisk's website rather than assumed from this article.

Tolerability

Gastrointestinal side effects, mainly nausea, are the most common issue during dose escalation and are usually manageable by slowing the titration schedule, eating smaller and lower-fat meals, and staying hydrated.

How long to continue

There is no established consensus on treatment duration for NASH specifically. Data from the weight-management trial program show that a substantial share of lost weight returns within a year of stopping semaglutide, which suggests that any liver benefit tied to weight loss would also be expected to erode after discontinuation, though this has not been directly studied in a liver-outcomes trial.

Safety considerations that apply regardless of indication

Semaglutide's labeled warnings include thyroid C-cell tumors observed in rodent studies (with uncertain human relevance, warranting contraindication in those with personal or family history of medullary thyroid carcinoma or MEN 2), acute pancreatitis, gallbladder complications, and acute kidney injury from dehydration due to gastrointestinal effects. MASH patients face compounded gallstone risk from both rapid weight loss and underlying metabolic disease, making acute right-upper-quadrant pain or jaundice symptoms requiring urgent medical attention.